Trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Observational study using serial ctDNA to infer recurrence risk in stage III and limited stage IV melanoma. ClinicalTrials.gov lists the study as completed.
Case Comprehensive Cancer Center
NCT07930182 is a recruiting, non-randomized phase 2 Moffitt trial (estimated enrollment 56) of neoadjuvant or adjuvant nivolumab, with ipilimumab added for ctDNA-defined escalation, using serial tumor-informed Haystack MRD plasma testing in resectable or resected cutaneous melanoma; primary endpoints are event-free survival in the neoadjuvant cohort and relapse-free survival in the adjuvant cohort.
H. Lee Moffitt Cancer Center and Research Institute